These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

841 related items for PubMed ID: 11795454

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA.
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [Abstract] [Full Text] [Related]

  • 27. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M, Mittendorf T.
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.
    Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V.
    Neurology; 2011 Apr 05; 76(14):1222-8. PubMed ID: 21464426
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 05; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.
    Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, Caputo D, Capra R, Bergamaschi R, North Italy Multiple Sclerosis Group.
    J Neurol Neurosurg Psychiatry; 2003 Dec 05; 74(12):1689-92. PubMed ID: 14638892
    [Abstract] [Full Text] [Related]

  • 39. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
    Pereira VC, Malfetano FR, Meira ID, Souza LF, Liem AM, Maiolino A, Alves-Leon SV.
    Arq Neuropsiquiatr; 2012 Oct 05; 70(10):774-9. PubMed ID: 23060103
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.